Coronary Artery Disease
Pipeline by Development Stage
Drug Modality Breakdown
Coronary Artery Disease is an $837M market that is mature and consolidating, dominated by a single P2Y12 antagonist class representing 83% of spending.
Key Trends
- Extreme market concentration: P2Y12 antagonists dominate with $699M (83% share) across just 2 products
- Multiple patent cliffs approaching (2026-2029), particularly CORLANOR ($47M) losing exclusivity in 2027
- Limited pipeline momentum: 965 total trials but 604 are unphased; Phase 3 activity (92 trials) suggests modest innovation pace
Career Verdict
Moderate career opportunity: stable revenue base and job growth, but limited innovation, high market concentration, and upcoming patent cliff erosion suggest specialization here is defensible only if you target niche mechanisms (e.g., colchicine inflammation, ivabradine HR reduction) or commercial/medical affairs roles.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | P2Y12 Receptor Antagonists (undisclosed brands) | Mixed (AstraZeneca, Amgen lead) | $699M | 83% | Peak | Stable | |
| 2 | CORLANOR (ivabradine) | Amgen | $47M | 6% | Peak | Declining | 1.1yr |
| 3 | AFINITOR DISPERZ (everolimus) | Novartis | $35M | 4% | Peak | Stable | 2.2yr |
| 4 | NITRO-DUR (nitroglycerin) | Pfizer | $3M | <1% | LOE_Approaching | Declining | |
| 5 | RANEXA (ranolazine) | Menarini | $2M | <1% | LOE_Approaching | Declining |
Drug Class Breakdown
market standard, stable
patent cliff approaching 2027
niche, patent cliff 2028
emerging evidence-based mechanism
legacy therapy, declining
patent cliff 2026
Career Outlook
StableCAD is a mature, stable indication with entrenched market leaders and limited innovation. Job growth is consistent but not robust, concentrated among large multinational companies. Specializing here offers job security in commercial and medical affairs roles but limited upside unless you target emerging mechanisms (colchicine, next-gen anticoagulants) or differentiated commercial strategies.
Breaking In
Enter via large companies (Abbott, J&J, AstraZeneca) in commercial or clinical operations; CAD is low-risk but offers limited specialty depth for early-career differentiation—consider it a foundation role while developing expertise in adjacent cardio-metabolic indications (heart failure, atrial fibrillation, hypertension).
For Experienced Professionals
If you have 7+ years in CAD, pivot toward emerging mechanisms (colchicine, GLP-1 combinations for CAD risk reduction) or shift to high-growth cardiovascular areas; staying pure CAD risks commoditization as P2Y12 patent cliffs accelerate generics and market consolidates further.
In-Demand Skills
Best For
Hiring Landscape
CAD-focused hiring is modest at 8,498 jobs across 15 companies, with Abbott, Johnson & Johnson, and AstraZeneca leading overall cardiovascular hiring. Commercial roles dominate (1,841 jobs at $230K avg) followed by engineering (900 jobs at $2.375M avg, likely medical device/diagnostics), suggesting commercial emphasis. Medical Affairs and Clinical Operations are secondary but stable growth areas.
Top Hiring Companies
By Department
Hiring is concentrated in established players (Abbott, J&J, AstraZeneca) with strong commercial and engineering focus; entry is competitive but stable for commercial, marketing, and clinical operations roles.
On Market (3)
Approved therapies currently available
Competitive Landscape
129 companies ranked by most advanced pipeline stage
+99 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 33,115 patients across 50 trials
Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization
Different Doses of Colchicine on hsCRP
The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)
Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease
Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI
Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
DynamX Bioadaptor Hong Kong Registry
Bioflow-DAPT Study
Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion
Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention
Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study
Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque
Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)
Using 3D Imaging to Optimize Bifurcation Stenting
Platelet Inhibition of Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention
EVOLVE Short DAPT Study
Vorapaxar on Thrombin Generation and Coagulability
Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation
ISAR-DAPT (A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial)
STEEL Percutaneous Coronary Intervention
Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM)
Contrast Enhancement on Coronary Computed Tomographic Angiography
Reversing Ticagrelor's Effects With Fresh Platelets
NIRS Ticagrelor Evaluation
Clopidogrel Versus Ticagrelor in Type-2 Diabetes
Ivabradine to Improve Endothelial Function in Patients With Coronary Artery Disease
Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor
Italian Diffuse/Multivessel Disease ABSORB Prospective Registry: IT-Disappears
Efficacy and Safety of Nano+ Polymer-free Sirolimus-Eluting Stent: A Optical Coherent Tomography Study
Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography
A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment
Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients
Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms
PROMUS Element Plus US Post-Approval Study
Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease
Evaluation of a Combined Near Infrared Spectroscopy (NIRS) and Intravascular Ultrasound (IVUS) Catheter for Detection of Lipid Rich Plaque
LONG-DES VI (Drug Eluting Stent for Long Lesions in Coronary Artery)
Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease
Diagnostic Study of Rapid Regadenoson Stress Cardiovascular Magnetic Resonance (CMR) to Detect Coronary Artery Disease
Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)
Efficacy and Safety of Xience in Coronary arEry Disease aLL-comers After stENTing Using the PRIME Platform (EXCELLENT-PRIME Registry)
Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients
Prophylactic Administration of Levosimendan in Patients Undergoing Coronary Surgery
Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography
The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease
Korean Multicenter Randomized Controlled Trial (RCT) of Pidogul for Patients With Coronary Stenting
Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor - Optimize Trial
Prasugrel/Clopidogrel Maintenance Dose Washout Study
ComparisiOn of Neointimal coVerage betwEen ZES and EES Using OCT at 3 Months
Related Jobs in Cardiovascular
Staff Data Scientist
Marketing Communications Manager
Senior Software Engineer - Backend
Senior Data Engineer - AI Empowerment
Senior Software Engineer - Frontend
Senior Technical Project Manager
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.